DNMT3A and myeloid neoplasm: The study reported that use of a spliceosome modulator was also shown to lead to sensitivity in isogeneic cell lines and decreased the leukemic burden in vivo. In many myeloid malignancies DNMT3A as well as TET2 are commutated with splicing factor mutations.